Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRD and 2nd ASCT in Relapsed Multiple Myeloma
NCT05497102Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Samsung Medical Center. Started Nov 2021; status: recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05497102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497102.